All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2019-12-12T16:48:53.000Z

CASSIOPET study: Is PET-CT a surrogate prognostic marker in transplant eligible patients with NDMM?

Dec 12, 2019
Share:

Bookmark this article

The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Philippe Moreau, University Hospital Hôtel-Dieu, Nantes, FR, answers the following question about the results of the CASSIOPET study: Is PET-CT a surrogate prognostic marker in transplant eligible patients with newly diagnosed multiple myeloma?

Philippe Moreau discusses the phase III, randomized CASSIOPET study, that looked at the effect of daratumumab in the context of stem cell transplantation. He discusses the efficacy of the drug regimen in the study arms. He also talks about the results of a trial that assessed the predictive value of PET-CT on patient outcomes.

CASSIOPET study: Is PET-CT a surrogate prognostic marker in transplant eligible patients with NDMM?

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox